Eli Lilly (LLY) plans to invest $3B in China over the next decade, the drugmaker said in a Chinese-language statement on Wednesday, according to Reuters. The company submitted a marketing application for its type-2 diabetes and obesity treatment orforglipron to China’s drug regulator at the end of 2025, Lilly said in its statement on WeChat, Reuters reported.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Portfolio Diversification to Investors
- Eli Lilly (LLY) Is Making a Big Bet on South Korea’s Biotech Sector. Here’s Why
- Why Is Hims & Hers Stock (HIMS) Soaring Today?
- Eli Lilly issues statement on CMMI BALANCE Model for GLP-1 medicines
- Amazon Pharmacy expands access to Eli Lilly Zepbound KwikPen